PointState Capital LP decreased its holdings in shares of Xencor Inc (NASDAQ:XNCR) by 0.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 473,400 shares of the biopharmaceutical company’s stock after selling 3,600 shares during the quarter. PointState Capital LP owned approximately 0.85% of Xencor worth $17,521,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. FMR LLC lifted its stake in Xencor by 2.4% in the second quarter. FMR LLC now owns 8,343,753 shares of the biopharmaceutical company’s stock valued at $308,802,000 after buying an additional 197,259 shares during the last quarter. BlackRock Inc. lifted its stake in Xencor by 28.5% in the second quarter. BlackRock Inc. now owns 4,011,155 shares of the biopharmaceutical company’s stock valued at $148,452,000 after buying an additional 889,181 shares during the last quarter. Redmile Group LLC lifted its stake in Xencor by 137.2% in the first quarter. Redmile Group LLC now owns 3,204,343 shares of the biopharmaceutical company’s stock valued at $96,066,000 after buying an additional 1,853,449 shares during the last quarter. First Light Asset Management LLC lifted its stake in Xencor by 8.2% in the first quarter. First Light Asset Management LLC now owns 697,756 shares of the biopharmaceutical company’s stock valued at $20,919,000 after buying an additional 52,992 shares during the last quarter. Finally, Franklin Resources Inc. lifted its stake in Xencor by 7.0% in the first quarter. Franklin Resources Inc. now owns 576,532 shares of the biopharmaceutical company’s stock valued at $17,284,000 after buying an additional 37,900 shares during the last quarter. Hedge funds and other institutional investors own 83.08% of the company’s stock.

In other news, major shareholder John S. Stafford III sold 53,767 shares of the company’s stock in a transaction that occurred on Monday, June 18th. The stock was sold at an average price of $39.88, for a total transaction of $2,144,227.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Paul A. Foster sold 36,341 shares of the company’s stock in a transaction on Thursday, August 16th. The stock was sold at an average price of $41.10, for a total value of $1,493,615.10. Following the transaction, the insider now directly owns 8,611 shares in the company, valued at approximately $353,912.10. The disclosure for this sale can be found here. Insiders have sold 491,651 shares of company stock valued at $19,697,311 in the last 90 days. Company insiders own 4.70% of the company’s stock.

A number of equities research analysts have weighed in on XNCR shares. BTIG Research started coverage on Xencor in a research note on Monday. They issued a “buy” rating and a $56.00 price objective for the company. BidaskClub cut Xencor from a “buy” rating to a “hold” rating in a research note on Friday, September 7th. Canaccord Genuity boosted their price objective on Xencor from $38.00 to $45.00 and gave the company a “buy” rating in a research note on Wednesday, August 8th. Zacks Investment Research upgraded Xencor from a “hold” rating to a “buy” rating and set a $47.00 price objective for the company in a research note on Friday, August 10th. Finally, ValuEngine upgraded Xencor from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, May 22nd. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $40.38.

Xencor stock opened at $47.25 on Friday. Xencor Inc has a 12 month low of $18.97 and a 12 month high of $47.70. The company has a market cap of $2.55 billion, a PE ratio of -45.00 and a beta of 1.61.

Xencor (NASDAQ:XNCR) last released its quarterly earnings results on Monday, August 6th. The biopharmaceutical company reported ($0.46) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.48) by $0.02. Xencor had a negative return on equity of 20.32% and a negative net margin of 137.35%. research analysts forecast that Xencor Inc will post -2.24 EPS for the current fiscal year.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.

Recommended Story: How to Invest in Marijuana Stocks

Want to see what other hedge funds are holding XNCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xencor Inc (NASDAQ:XNCR).

Institutional Ownership by Quarter for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.